BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 35163129)

  • 21. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer.
    Kumari N; Singh RK; Mishra SK; L R; Mohindra S; Krishnani N
    Pathol Res Pract; 2021 Jan; 217():153309. PubMed ID: 33341547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Familial pancreatic cancer: Concept, management and issues.
    Matsubayashi H; Takaori K; Morizane C; Maguchi H; Mizuma M; Takahashi H; Wada K; Hosoi H; Yachida S; Suzuki M; Usui R; Furukawa T; Furuse J; Sato T; Ueno M; Kiyozumi Y; Hijioka S; Mizuno N; Terashima T; Mizumoto M; Kodama Y; Torishima M; Kawaguchi T; Ashida R; Kitano M; Hanada K; Furukawa M; Kawabe K; Majima Y; Shimosegawa T
    World J Gastroenterol; 2017 Feb; 23(6):935-948. PubMed ID: 28246467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome.
    Lener MR; Kashyap A; Kluźniak W; Cybulski C; Soluch A; Pietrzak S; Huzarski T; Gronwald J; Lubiński J
    Cancer Res Treat; 2017 Apr; 49(2):430-436. PubMed ID: 27488870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
    Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
    Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
    Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
    PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
    Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
    Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic testing by cancer site: pancreas.
    Axilbund JE; Wiley EA
    Cancer J; 2012; 18(4):350-4. PubMed ID: 22846737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
    Vietri MT; D'Elia G; Caliendo G; Resse M; Casamassimi A; Passariello L; Albanese L; Cioffi M; Molinari AM
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.
    Roberts NJ; Norris AL; Petersen GM; Bondy ML; Brand R; Gallinger S; Kurtz RC; Olson SH; Rustgi AK; Schwartz AG; Stoffel E; Syngal S; Zogopoulos G; Ali SZ; Axilbund J; Chaffee KG; Chen YC; Cote ML; Childs EJ; Douville C; Goes FS; Herman JM; Iacobuzio-Donahue C; Kramer M; Makohon-Moore A; McCombie RW; McMahon KW; Niknafs N; Parla J; Pirooznia M; Potash JB; Rhim AD; Smith AL; Wang Y; Wolfgang CL; Wood LD; Zandi PP; Goggins M; Karchin R; Eshleman JR; Papadopoulos N; Kinzler KW; Vogelstein B; Hruban RH; Klein AP
    Cancer Discov; 2016 Feb; 6(2):166-75. PubMed ID: 26658419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    Sorscher S; Ansley K; Delaney SD; Ramkissoon S
    Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline mutations in pancreatic cancer and potential new therapeutic options.
    Pihlak R; Valle JW; McNamara MG
    Oncotarget; 2017 Sep; 8(42):73240-73257. PubMed ID: 29069866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
    Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
    PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.
    Rainone M; Singh I; Salo-Mullen EE; Stadler ZK; O'Reilly EM
    JAMA Oncol; 2020 May; 6(5):764-771. PubMed ID: 32053139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of
    Pilarski R
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():79-86. PubMed ID: 31099688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
    Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
    Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.
    Aslanian HR; Lee JH; Canto MI
    Gastroenterology; 2020 Jul; 159(1):358-362. PubMed ID: 32416142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized Systemic Therapies in Hereditary Cancer Syndromes.
    Mastrodomenico L; Piombino C; Riccò B; Barbieri E; Venturelli M; Piacentini F; Dominici M; Cortesi L; Toss A
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
    DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
    Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.